Abstract
The osteoporotic fracture rate in patients with chronic liver disease is approximately twice that of age-matched, control individuals. About 66% of patients with moderately severe cirrhosis and 96% of patients awaiting liver transplantation have vitamin D deficiency. Studies have shown a strong correlation between vitamin D deficiency and bone density, particularly in the hip. Previous studies of vitamin D therapy in cirrhosis-related bone disease have had major design flaws. Most reports and guidelines on the treatment of hepatic bone disease have concluded that vitamin D deficiency does not have a significant pathogenetic role in the development of osteoporosis in cirrhosis, and that there is no evidence for a therapeutic effect of vitamin D supplementation. Conversely, it is generally recommended that patients with cirrhosis and low bone density should receive calcium and vitamin D supplementation; yet there is a paucity of reliable data on the optimal doses to use, as well as a lack of clearly demonstrated benefit. We believe that clinical trials of vitamin D therapy in these patients with liver disease are warranted. As low-dose oral supplementation often will not normalize vitamin D levels or suppress parathyroid hormone activity in cirrhotic patients, high-dose, parenteral vitamin D might be preferable, but further long-term studies are required to assess the benefits and safety of this approach.
Key Points
-
Vitamin D deficiency is common in patients with cirrhosis, and its severity correlates with the progression of cirrhosis
-
Vitamin D deficiency in cirrhotic patients is strongly correlated with bone density changes, particularly in the hip
-
Some patients with vitamin D deficiency and cirrhosis develop secondary hyperparathyroidism; it is not known whether the presence or absence of hyperparathyroidism correlates with changes in bone density or fracture risk
-
The etiology of vitamin D deficiency in patients with cirrhosis is multifactorial and might include lack of sunlight, impaired intestinal absorption and disruption of the enterohepatic cycle
-
Most guidelines recommend calcium and vitamin D supplementation in patients with cirrhosis and low bone density, but there have been no randomized, controlled studies of an adequate scale to assess the effects of such supplementation on bone density or osteoporotic fracture rates
-
Vitamin D deficiency and secondary hyperparathyroidism should be corrected before initiation of bisphosphonate therapy for osteoporosis
-
High-dose, parenteral vitamin D therapy might be beneficial for patients with cirrhosis and vitamin D deficiency; however, further studies are required to assess the potential risks (e.g. hypercalcuria) of this approach
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Leslie W et al. (2003) AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 125: 941–966
Diamond T et al. (1989) Serum vitamin D metabolites are not responsible for low turnover osteoporosis in chronic liver disease. J Clin Endocrinol Metab 69: 1234–1239
Collier J et al. (2002) Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 50 (Suppl 1): i1–i9
Crawford B et al. (2003) The heterogeneity of bone disease in cirrhosis: a multivariate analysis. Osteoporosis Int 14: 987–994
American Gastroenterological Association (2003) American Gastroenterological Association medical position statement: osteoporosis in hepatic disorders. Gastroenterology 125: 937–940
McCaughan G and Feller R (1994) Osteoporosis in chronic liver disease: pathogenesis, risk factors, and management. Dig Dis 12: 223–231
Hay J (1995) Bone disease in cholestatic liver disease. Gastroenterology 108: 276–283
Rouillard S and Lane N (2001) Hepatic osteodystrophy. Hepatology 33: 301–307
Hay J (2003) Osteoporosis in liver diseases and after liver transplantation. J Hepatol 38: 856–865
Working Group of the Australian and New Zealand Bone and Mineral Society Endocrine Society of Australia and Osteoporosis Australia (2005) Vitamin D and adult bone health in Australia and New Zealand: a position statement. Med J Aust 182: 281–285
Samanek A et al. (2006) Estimates of beneficial and harmful sun exposure times during the year for major Australian population centres. Med J Aust 184: 338–341
Bikle D et al. (1986) Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J Clin Endocrinol Metab 63: 954–959
Gray R et al. (1978) Metabolism and excretion of 3H-1,25-(OH)2-D3 in healthy adults. J Clin Endocrinol Metab 46: 756–765
Binkley N et al. (2004) Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab 89: 3152–3157
Hollis B (2004) The determination of circulating 25-hydroxyvitamin D: no easy task [editorial]. J Clin Endocrinol Metab 89: 3149–3151
Carmeliet G et al. (1999) The vitamin D hormone and its nuclear receptor: genomic mechanisms involved in bone biology. In Dynamics of Bone and Cartilage Metabolism (eds Seibel M et al.) San Diego: Academic Press
Compston J (1986) Hepatic osteodystrophy: vitamin D metabolism in patients with liver disease. Gut 27: 1073–1090
Barragry J et al. (1978) Plasma vitamin D-binding globulin in vitamin D deficiency, pregnancy and chronic liver disease. Clin Chim Acta 87: 359–365
Bikle D et al. (1986) Free 25-hydroxyvitamin D levels are normal in subjects with liver disease and reduced total 25-hydroxyvitamin D levels. J Clin Invest 78: 748–752
Masuda S et al. (1989) Concentrations of vitamin D-binding protein and vitamin D metabolites in plasma of patients with liver cirrhosis. J Nutr Sci Vitaminol (Tokyo) 35: 225–234
Jung R et al. (1978) Abnormal vitamin D metabolism in cirrhosis. Gut 19: 290–293
White P and Cooke N (2000) The multifunctional properties and characteristics of vitamin D-binding protein. Trends Endocrinol Metab 11: 320–327
Dibble J et al. (1984) A survey of vitamin D deficiency in gastroenterological and liver disorders. Q J Med 209: 119–134
Sahota O et al. (1999) Vitamin D insufficiency increases bone turnover markers and enhances bone loss at the hips in patients with established osteoporosis. Clin Endocrinol 51: 217–221
Meunier P (2001) Vitamin D insufficiency: reappraisal of its definition threshold and bone consequences. In Nutritional Aspects of Osteoporosis, 167–172 (eds Burckhardt P et al.) San Diego: Academic Press
Vieth R et al. (2003) Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J Clin Endocrinol Metab 88: 185–191
Wills M and Savory J (1984) Vitamin D metabolism and chronic liver disease. Ann Clin Lab Sci 14: 189–197
Heaf J (1985) Hepatic osteodystrophy. Scand J Gastroenterol 20: 1035–1040
Matloff D et al. (1982) Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology 83: 97–102
Skinner R et al. (1977) 25-hydroxylation of vitamin D in primary biliary cirrhosis. Lancet 1: 720–721
Mawer E et al. (1985) Metabolism of vitamin D in patients with primary biliary cirrhosis and alcoholic liver disease. Clin Sci (Lond) 69: 561–570
Davies M et al. (1983) Vitamin D deficiency, osteomalacia, and primary biliary cirrhosis. Response to orally administered vitamin D3 . Dig Dis Sci 28: 145–153
Plourde V et al. (1988) Severe cholestasis leads to vitamin D depletion without perturbing its C-25 hydroxylation in the dog. Hepatology 8: 1577–1585
Plourde V et al. (1988) Hepatic handling of vitamin D3 in micronodular cirrhosis: a structure–function study in the rat. J Bone Miner Res 3: 461–471
Goldsmith R (1982) Enterohepatic cycling of vitamin D and its metabolites. Miner Electrolyte Metab 8: 289–292
Fraser D (1983) The physiological economy of vitamin D. Lancet 1: 969–971
Compston J and Ledger J (1983) Vitamin D. Lancet 2: 45–46
Clements M et al. (1984) Enterohepatic circulation of vitamin D: a reappraisal of the hypothesis. Lancet 1: 1376–1379
Gascon-Barre M and Joly J (1981) The biliary excretion of [3H]-25-hydroxyvitamin D3 following chronic ethanol administration in the rat. Life Sci 28: 279–286
Davies M et al. (1997) Increased catabolism of 25-hydroxyvitamin D in patients with partial gastrectomy and elevated 1,25 dihydroxyvitamin D levels. Implications for metabolic bone disease. J Clin Endocrinol Metab 82: 209–212
Clements M et al. (1987) A new mechanism for induced vitamin D deficiency in calcium deprivation. Nature 325: 62–65
Chen C et al. (1996) Metabolic bone disease of liver cirrhosis: is it a parallel to the clinical severity of cirrhosis? J Gastroenterol Hepatol 11: 417–421
Sahota O et al. (2004) The relationship between vitamin D and parathyroid hormone: calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis. Bone 35: 312–319
Dibble J et al. (1981) Evidence for secondary hyperparathyroidism in the osteomalacia associated with chronic liver disease. Clin Endocrinol 15: 373–383
Crippin J et al. (1994) Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am J Gastroenterol 89: 47–50
Herlong H et al. (1982) Bone disease in primary biliary cirrhosis: histological features and response to 25-hydroxyvitamin D. Gastroenterology 83: 103–108
Reed J et al. (1980) Bone disease in primary biliary cirrhosis: reversal of osteomalacia with oral 25-hydroxyvitamin D. Gastroenterology 78: 512–517
Compston J et al. (1980) Vitamin D prophylaxis and osteomalacia in chronic cholestatic liver disease. Dig Dis Sci 25: 28–32
Mobarhan S et al. (1984) Metabolic bone disease in alcoholic cirrhosis: a comparison of the effect of vitamin D2, 25-hydroxyvitamin D, or supportive treatment. Hepatology 4: 266–273
Shiomi S et al. (1999) Calcitriol for bone disease in patients with cirrhosis of the liver. J Gastroenterol Hepatol 14: 547–552
Floreani A et al. (1997) A 3-year pilot study with 1, 25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis. J Clin Gastroenterol 24: 239–244
Tilyard M et al. (1992) Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326: 357–362
Neer R et al. (1992) Calcitriol or calcium for postmenopasual osteoporosis [letter]. N Engl J Med 327: 284
Ebeling P et al. (2001) Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double-blind placebo study. J Clin Endocrinol Metab 86: 4098–4103
Kalef-Ezra J et al. (1996) Amount and composition of bone minerals in chronic liver disease. Dig Dis Sci 41: 1008–1013
Bonkovsky H et al. (1990) Prevalence and prediction of osteopenia in chronic liver disease. Hepatology 12: 273–280
Sahota O et al. (2006) Vitamin D insufficiency and the blunted PTH response in established osteoporosis: the role of magnesium deficiency. Osteoporosis Int 17: 1013–1021
Lips P (2001) Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 22: 477–501
Souberbielle J-C et al. (2001) Vitamin D status and redefining serum parathyroid hormone reference range in the elderly. J Clin Endocrinol Metab 86: 3086–3090
Sambrook P et al. (2004) Serum parathyroid hormone is associated with increased mortality independent of 25-hydroxyvitamin D status, bone mass, and renal function in the frail and very old: a cohort study. J Clin Endocrinol Metab 89: 5477–5481
McKenna M and Freaney R (1998) Secondary hyperparathyroidism in the elderly: means to define hypovitaminosis D. Osteoporosis Int 8 (Suppl 2): S3–S6
Steingrimsdottir L et al. (2005) Relationship between serum parathyroid hormone levels, vitamin D sufficiency and calcium intake. JAMA 294: 2336–2341
Conigrave A et al. (2000) L-amino acid sensing by the extracellular Ca2+ sensing receptor. Proc Natl Acad Sci USA 97: 4814–4819
Papadimitropoulos E et al. (2002) Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 23: 560–569
Bischoff-Ferrari H et al. (2005) Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 293: 2257–2264
The RECORD Trial Group (2005) Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D): a randomised placebo-controlled trial. Lancet 365: 1621–1628
Cooper L et al. (2003) Vitamin D supplementation and bone mineral density in early postmenopausal women. Am J Clin Nutr 77: 1324–1329
Reis A et al. (2005) Vitamin D endocrine system and the genetic susceptibility to diabetes, obesity and vascular disease. A review of evidence. Diabetes Metab 31: 318–325
Holick M (2005) Vitamin D: important for prevention of osteoporosis, cardiovascular heart disease, type 1 diabetes, autoimmune disease, and some cancers. South Med J 98: 1024–1027
Holick M (2006) High prevalence of vitamin D inadequacy and implications for health. Mayo Clinic Proc 81: 353–373
Liu S et al. (2005) Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older US women. Diabetes Care 28: 2926–2932
Forman J et al. (2005) Vitamin D intake and the risk of incident hypertension. Hypertension 46: 676–682
Black P and Scragg R (2005) Relationship between 25-hydroxyvitamin D and pulmonary function in the third national health and nutritional examination survey. Chest 128: 3792–3798
Schleithoff S et al. (2006) Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 83: 754–759
Garland C et al. (2006) The role of vitamin D in cancer prevention. Am J Public Health 96: 252–261
Grant W (2006) Lower vitamin-D production from solar ultraviolet-B irradiance may explain some differences in cancer survival rates. J Natl Med Assoc 98: 357–364
Pfeifer M et al. (2002) Vitamin D and muscle function. Osteoporosis Int 13: 187–194
Gerdhem P et al. (2005) Association between 25-hydroxyvitamin D levels, physical activity, muscle strength and fractures in the prospective population-based OPRA Study of Elderly Women. Osteoporosis Int 16: 1425–1431
Staud R (2005) Vitamin D: more than just affecting calcium and bone. Curr Rheumatol Rep 7: 356–364
Teoh N and Farrell G (2004) Management of chronic hepatitis C virus infection: a new era of disease control. Intern Med J 34: 324–337
Trang H et al. (1998) Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2 . Am J Clin Nutr 68: 854–858
Armas L et al. (2004) Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 89: 5387–5391
Holmberg I et al. (1986) 25-hydroxylase activity in subcellular fraction from human liver. Evidence for different rates of mitochondrial hydroxylation of vitamin D2 and D3 . Scand J Clin Lab Invest 46: 785–790
Diamond T et al. (2005) Annual intramuscular injection of a megadose of cholecalciferol for treatment of vitamin D deficiency: efficacy and safety data. Med J Aust 183: 10–12
Cranney A et al. (2002) Meta-analyses of therapies for postmenopausal osteoporosis. I. Systematic reviews of randomized trials in osteoporosis: introduction and methodology. Endocr Rev 23: 496–507
Sambrook P (2005) How to prevent steroid-induced osteoporosis. Ann Rheum Dis 64: 176–178
Crawford B et al. (2006) Zoledronic acid prevents bone loss following liver transplantation—a randomised, placebo-controlled trial. Ann Intern Med 144: 239–248
MacIsaac R et al. (2002) Seizures after alendronate. J R Soc Med 95: 615–616
Van Staa T et al. (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15: 1001–1005
Acknowledgements
The authors thank Associate Professor Rebecca Mason, Department of Physiology, University of Sydney, Australia, for her comments on this paper.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Crawford, B., Labio, E., Strasser, S. et al. Vitamin D replacement for cirrhosis-related bone disease. Nat Rev Gastroenterol Hepatol 3, 689–699 (2006). https://doi.org/10.1038/ncpgasthep0637
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep0637
This article is cited by
-
LC/MS analysis of vitamin D metabolites by dielectric barrier discharge ionization and a comparison with electrospray ionization and atmospheric pressure chemical ionization
Analytical and Bioanalytical Chemistry (2018)
-
Activation of Reactive MALDI Adduct Ions Enables Differentiation of Dihydroxylated Vitamin D Isomers
Journal of the American Society for Mass Spectrometry (2017)
-
Bone health and vitamin D status in alcoholic liver disease
Indian Journal of Gastroenterology (2016)
-
Osteodystrophy in chronic liver diseases
Internal and Emergency Medicine (2013)
-
Bone Disorders in Chronic Liver Diseases
Current Gastroenterology Reports (2011)